Biologic treatment eligibility and characteristics of Romanian patients with severe asthma: Real-world data from the RECOGNISE study

1 Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022. Available from: http://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf [Accessed 8th January 2023]. Search in Google Scholar

2 Song P, Adeloye D, Salim H, Dos Santos JP, Campbell H, Sheikh A, et al. Global, regional, and national prevalence of asthma in 2019: a systematic analysis and modelling study. J Glob Health. 2022;12: 04052. doi:10.7189/jogh.12.04052 Search in Google Scholar

3 GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396: 1204–1222. doi:10.1016/S0140-6736(20)30925-9 Search in Google Scholar

4 Eurostat. Finland: EU country with highest share of asthmatics. 2021. Available from: http://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20210924-20210921. [Accessed 8th January 2023.] Search in Google Scholar

5 Caminati M, Senna G. Uncontrolled severe asthma: starting from the unmet needs. Current Medical Research and Opinion. 2019;35: 175–177. doi:10.1080/03007995.2018.1528218 Search in Google Scholar

6 Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, et al. Severe asthma and biologic therapy: when, which, and for whom. Pulmonary Therapy. 2020;6: 47–66. doi:10.1007/s41030-019-00109-1 Search in Google Scholar

7 Roche N, Garcia G, de Larrard A, Cancalon C, Bénard S, Perez V, et al. Real-life impact of uncontrolled severe asthma on mortality and healthcare use in adolescents and adults: findings from the retrospective, observational RESONANCE study in France. BMJ Open. 2022;12: e060160. doi:10.1136/bmjopen-2021-060160 Search in Google Scholar

8 Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology. 2014;43: 343–373. doi:10.1183/09031936.00202013 Search in Google Scholar

9 Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology. 2020;55: 1900588. doi:10.1183/13993003.00588-2019 Search in Google Scholar

10 Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, et al. EAACI biologics guidelines-recommendations for severe asthma. Allergy. 2021;76: 14–44. doi:10.1111/all.14425 Search in Google Scholar

11 Frix AN, Heaney LG, Dahlén B, Mihaltan F, Sergejeva S, Popović-Grle S, et al. Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study. ERJ Open Research. 2022;8: 00273–2022. doi:10.1183/23120541.00273-2022 Search in Google Scholar

12 Porsbjerg CM, Menzies-Gow AN, Tran TN, Murray RB, Unni B, Audrey Ang SL, et al. Global variability in administrative approval prescription criteria for biologic therapy in severe asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10: 1202–16.e23. doi:10.1016/j.jaip.2021.12.027 Search in Google Scholar

13 Kanniess F, Tamasi L, Mroz RR, Bakakos P, Tubis S, Plat GR, et al. Real-world patient characteristics and eligibility for biologics in severe asthma (RECOGNISE). European Respiratory Journal. 2021;58: A3729. doi: 10.1183/13993003.congress-2021.PA3729 Search in Google Scholar

14 Global Initiative for Asthma. Pocket guide for asthma management and prevention. A pocket guide for health professionals. Updated 2017. Available from: http://ginasthma.org/wp-content/uploads/2017/02/wms-Main-pocket-guide_2017.pdf [Accessed 8th January 2023.] Search in Google Scholar

15 Jones PW, Quirk FH, Baveystock CM. The St. George’s respiratory questionnaire. Respiratory Medicine. 1991;85(Suppl B): 25–31. doi:10.1016/S0954-6111(06)80166-6 Search in Google Scholar

16 Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine. 2005;99: 553–558. doi:10.1016/j.rmed.2004.10.008 Search in Google Scholar

17 Yang CC, Fong Y, Lin LC, Que J, Ting WC, Chang CL, et al. The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices. European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery. 2018;53: 235–240. doi:10.1093/ejcts/ezx215 Search in Google Scholar

18 Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. The Journal of Asthma: Official Journal of the Association for the Care of Asthma. 2018;55: 152– 160. doi:10.1080/02770903.2017.1322611 Search in Google Scholar

19 Jeimy S, Tsoulis MW, Hachey J, Kim H. Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective. Allergy, Asthma, and Clinical Immunology. 2018;14: 68. doi:10.1186/s13223-018-0301-6 Search in Google Scholar

20 Marques Mello L, Viana KP, Moraes Dos Santos F, Saturnino LTM, Kormann ML, Lazaridis E, et al. Severe asthma and eligibility for biologics in a Brazilian cohort. The Journal of Asthma: Official Journal of the Association for the Care of Asthma. 2021;58: 958– 966. doi:10.1080/02770903.2020.1748049 Search in Google Scholar

21 Bakakos P, Tryfon S, Palamidas A, Mathioudakis N, Galanakis P. Patient characteristics and eligibility for biologics in severe asthma: results from the Greek cohort of the RECOGNISE “real world” study. Respiratory Medicine. 2023;210: 107170. doi:10.1016/j.rmed.2023.107170 Search in Google Scholar

22 Bumbacea D, Panaitescu C, Bumbacea RS. Patient and physician perspectives on asthma and its therapy in Romania: results of a multicenter survey. Medicina (Kaunas). 2021;57: 1089. doi:10.3390/medicina57101089 Search in Google Scholar

23 Chen W, Sadatsafavi M, Tran TN, Murray RB, Wong CBN, Ali N, et al. Characterization of patients in the international severe asthma registry with high steroid exposure who did or did not initiate biologic therapy. Journal of Asthma and Allergy. 2022;15: 1491–1510. doi:10.2147/JAA.S377174 Search in Google Scholar

24 Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. The European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology. 2015;46: 1308–1321. doi:10.1183/13993003.00779-2015 Search in Google Scholar

25 Heffler E, Blasi F, Latorre M, Menzella F, Paggiaro P, Pelaia G, et al. The severe asthma network in Italy: findings and perspectives. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7: 1462–1468. doi:10.1016/j.jaip.2018.10.016 Search in Google Scholar

26 Kim MH, Kim SH, Park SY, Ban GY, Kim JH, Jung JW, et al. Characteristics of adult severe refractory asthma in Korea analyzed from the severe asthma registry. Allergy, Asthma & Immunology Research. 2019;11: 43–54. doi:10.4168/aair.2019.11.1.43 Search in Google Scholar

27 Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, et al. Efficacy and safety of treatment with biologics ( benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologics in severe asthma. Allergy. 2020;75: 1023–1042. doi:10.1111/all.14221 Search in Google Scholar

28 Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9: 2702–2714. doi:10.1016/j.jaip.2021.01.011 Search in Google Scholar

29 Charles D, Shanley J, Temple SN, Rattu A, Khaleva E, Roberts G. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology. 2022;52: 616–627. doi:10.1111/cea.14112 Search in Google Scholar